ClinicalTrials.gg
RecruitingNCT02635022Updated Dec 23, 2025

Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study

An observational study in Osteoporosis and Fracture, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by National Taiwan University Hospital · Observational

From the registry’s dates

  • Started Sep 2015; still recruiting 11 years 2 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
50 Years and older
Sex
All
01

Study summary

Aims: (1) to Establish the FLS services at the National Taiwan University Hospital Jinshan Branch. (2) To establish a anti-osteoporosis medication management service at Jinshan Branch.

Method: From Aug., 2015, a fracture liaison services (FLSs) following the 13 'Capture the Fracture Best Practice Standards' were implemented at the National Taiwan University Hospital Jinshan Branch health care system. The Jinshan Branch program enrolled patient with 1) new hip fracture 2) newly identified vertebral fractures (radiological or clinical) from both inpatients and outpatients. At the same time, a osteoporosis medication management service is also establish as a complement of FLS to enroll patients on antiosteoporosis medications (AOMs) but not necessary with fracture.

Participating physicians will select those eligible for services and refer to study coordinators. Study coordinators will conduct baseline assessments on osteoporosis/fracture risks, record medical conditions, AOMs, provide educations on osteoporosis, fracture, sarcopenia, fall, medications, nutrition, and exercise. They also arrange return clinic visit, telephone reminder and follow up for patients, and communicate with providers on regular bases.

During the whole study period, the investigators planed to enroll 200 patients (with or without fracture). Each patient would be assessed at baseline, and every 4 months last for two years.

Read the detailed description

Background:The Asia Fracture Gap Taiwan Study (AFGTS) showed that among fragility fracture sufferers, only 1/4 of them underwent bone mineral density (BMD) tests and 1/3 of them received treatments for osteoporosis. Secondary fragility fracture prevention services are needed to improve the care gaps. In addition, one-year adherence to oral anti-osteoporosis medication (AOMs) was only about 30%. In recent years, efforts have been made to change the delivery of these medications from oral form to injection form every, 3, 6 or 12 months to increase adherence. However, both patients and providers are sometimes confused about the multiple choices. Also, patients may receive extra medications if providers did not keep tract of their previous AOM uses or patients may changes providers. There were urgent needs to provide AOM monitoring and management services to improve cares.

. Aims: (1) to Establish the FLS services at the National Taiwan University Hospital Jinshan Branch. (2) To establish a anti-osteoporosis medication management service at Jinshan Branch.

Method: The FMS was designed following the 13 'Capture the Fracture Best Practice Standards'. The National Taiwan University Hospital (NTUH) institutional review board approved the study in Aug., 2015. Patients were eligible to be enrolled into the FMS part of the study if they had

  • Age >=50 and one of the below
  • New hip fracture in orthopedic ward
  • Newly identified radiographic vertebral fractures from plan films in geriatric ward or clinical vertebral fractures in outpatient clinics
  • Newly prescribed with AOMs
  • Recent change of AOMs
  • Poor adherence to AOMs
  • Participating physicians feel that the service will benefit the patient in overall osteoporosis and medication managements.

Exclusion Criteria:

  • Life expectancy less than 2 years or can't be assessed for communication problems
  • Atypical fractures
  • Patient in other medication clinical trials
  • Unwilling to accept the assessment and treatment

Osteoporosis-related assessments, treatments, consultations on diet, medications, exercise, fall prevention were given mainly by care managers. A system is set up to remind patients to take their medications at home or to return to clinic for regular injections of medications. Follow up assessments included adherence to education instructions, medications, fall and fracture incidences. During the whole study period, we planed to enroll 200 patients. Each patient would be assessed at baseline, and every 4 months last for two years.

Anticipated results:

Establish Osteoporosis-related patient database combined with NTUH Participating physicians and care managers will learn new skills in managing osteoporosis patients.

Enhance adherence to AOMs The results published in the International Osteoporosis Conferences

02

Conditions studied

  • Osteoporosis
  • Fracture

Keywords

  • Fracture
  • Sarcopenia
  • Osteoporosis
  • Care management
  • Medication adherence
03

In context

Osteoporosis

1,601 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

This study's planned enrollment of 200 is above the median of 160 across 455 observational studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,615 studies on the registry; 576 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

new fragility fracture Adults treated with anti-osteoporosis medicines (AOMs)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=50 and one of the below
  • New hip fracture in orthopedic ward
  • Newly identified radiographic vertebral fractures from plan films in geriatric ward or clinical vertebral fractures in outpatient clinics
  • Newly prescribed with AOMs
  • Recent change of AOMs
  • Poor adherence to AOMs
  • Participating physicians feel that the service will benefit the patient in overall osteoporosis and medication managements.

Exclusion criteria

Exclusion Criteria:

  • less than 2 years or can't be assessed for communication problems
  • Atypical fractures
  • Patient in other medication clinical trials
  • Unwilling to accept the assessment and treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • FLS

    Patients with new hip fracture or newly identified vertebral fractures

  • MMS

    Patients prescribed with anti-osteoporosis medications but not fit FLS requirements

06

What researchers measure

Primary outcomes

  1. Changes of medication adherence

    Changes of medication adherence for all participants will be assessed at the 4, 8, 12, 18 and 24 months after enrollments. However, the main primary outcome will be set at the adherence at 12 months. If the patient changes medication, all AOMs adherence will be combined. Specific formulas of medication adherence assessments are as below: 1. for oral medications: adherence is defined as: medication taken/ medication prescribed within past 3 months 2. for injection medications: adherence is defined as: of injection/ of due injection since baseline or last follow up phone call. Statistics: Simple counts of adherence (%) among all participants.

    Time frame: 12 MONTHS

Secondary outcomes

  1. The proportion of patients received Bone Mineral Density test within 8 week after enrollments

    This outcome is concerned with the percentage of FLS patients received BMD test at the timing (8 week) of when post-fracture assessment is done.

    Time frame: 8 week

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2015 (actual). Primary completion is estimated for Dec 2026, 135 months after the start.

Of 114 non-industry observational studies under Osteoporosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 113. This study's planned 135 months is above that.

Counting every sponsor, half of 125 studies reached it within 51 months; a quarter within 24 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2015
First posted
Dec 18, 2015
StartActual
Sep 2015
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02635022
Responsible party
Sponsor
First posted
Dec 18, 2015
Start date
Sep 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Ding-Cheng Chan, MD, PhD
Contact
doctord6226@yahoo.com
886-2-23123456 ext. 67786
Ding-Cheng Chan, MD, PhD
principal investigator · National Taiwan University Hospital, Chutung branch

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion